HOYA Vision Care, Amsterdam, the Netherlands.
Optometry and Visual Sciences, City, University of London, London, UK.
Ophthalmic Physiol Opt. 2024 Sep;44(6):1248-1260. doi: 10.1111/opo.13366. Epub 2024 Jul 31.
Myopia and especially high myopia are recognised as major public health concerns. Although the prevalence of high myopia in young children is low, 10-20% of high school children in Asia have high myopia, with many still progressing, and one in three patients with high myopia develop visual impairment with age. Most participants in myopia control studies have low and moderate myopia; relatively little is known about myopia control in high myopia.
Literature searches were undertaken in MEDLINE and EMBASE to identify publications in English, investigating (Aim 1) the efficacy of myopia control strategies (environmental, pharmacological and optical) in high myopia (≤-6.00 D) and (Aim 2) the complications of high myopia using keywords. Outcomes included change in spherical equivalent refractive error (SE) and/or axial length (AL) to evaluate progression in high myopia.
Aim 1: Twelve studies were identified that reported the efficacy of optical and pharmacological (none on environmental) interventions on AL and SE for high myopia control. A statistically significant reduction in progression of SE and AL in high myopes was reported with 1% and 0.5% atropine. Defocus Incorporated Multiple Segment spectacle lenses had lower efficacy in slowing high myopia progression compared to moderate and low myopia. Ortho-K lenses were equally effective in reducing myopia progression in low, moderate and high myopia. Aim 2: Myopic patients have an increased risk of myopic macular degeneration, retinal detachment, cataract and glaucoma, with the risk increasing with the level of myopia.
High myopia has significant effects on quality of life, risk of pathological complications and vision impairment. Young children, excluding those with some syndromic associations, who are fast progressing moderate and high myopes require early intervention and close monitoring. Further research investigating the efficacy of myopia control strategies in highly myopic patients, both independently and through combination treatments, are necessary.
近视,尤其是高度近视,已被公认为重大公共卫生问题。虽然幼儿高度近视的患病率较低,但亚洲有 10-20%的高中生患有高度近视,其中许多仍在进展,三分之一的高度近视患者会随着年龄增长而出现视力损害。大多数近视控制研究的参与者都患有低度和中度近视;对于高度近视的近视控制,我们知之甚少。
在 MEDLINE 和 EMBASE 中进行文献检索,以确定用英文发表的研究,旨在(目的 1)评估高度近视(≤-6.00 D)中各种近视控制策略(环境、药物和光学)的疗效,以及(目的 2)使用关键词评估高度近视的并发症。主要结局包括评估高度近视进展的球镜等效屈光度(SE)和/或眼轴(AL)变化。
目的 1:共确定了 12 项研究,这些研究报告了光学和药物干预(无环境干预)对高度近视控制的 AL 和 SE 的疗效。报道称,使用 1%和 0.5%阿托品可显著减缓高度近视患者的 SE 和 AL 进展。离焦型多焦点框架眼镜在减缓高度近视进展方面的疗效低于中低度近视。角膜塑形镜(OK 镜)在减缓低度、中度和高度近视进展方面同样有效。目的 2:近视患者发生近视性黄斑病变、视网膜脱离、白内障和青光眼的风险增加,且风险随近视程度的增加而增加。
高度近视会显著影响生活质量、病理性并发症风险和视力损害。需要对进展迅速的中高度近视儿童(除了某些综合征相关患者)进行早期干预和密切监测。还需要进一步研究评估近视控制策略对高度近视患者的疗效,包括单独使用和联合使用。